The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: Guideline methodology

Abstract Extracorporeal treatments (ECTRs), such as hemodialysis and hemoperfusion, are used in poisoning despite a lack of controlled human trials demonstrating efficacy. To provide uniform recommendations, the EXTRIP group was formed as an international collaboration among recognized experts from nephrology, clinical toxicology, critical care, or pharmacology and supported by over 30 professional societies. For every poison, the clinical benefit of ECTR is weighed against associated complications, alternative therapies, and costs. Rigorous methodology, using the AGREE instrument, was developed and ratified. Methods rely on evidence appraisal and, in the absence of robust studies, on a thorough and transparent process of consensus statements. Twenty-four poisons were chosen according to their frequency, available evidence, and relevance. A systematic literature search was performed in order to retrieve all original publications regardless of language. Data were extracted on a standardized instrument. Quality of the evidence was assessed by GRADE as: High = A, Moderate = B, Low = C, Very Low = D. For every poison, dialyzability was assessed and clinical effect of ECTR summarized. All pertinent documents were submitted to the workgroup with a list of statements for vote (general statement, indications, timing, ECTR choice). A modified Delphi method with two voting rounds was used, between which deliberation was required. Each statement was voted on a Likert scale (1–9) to establish the strength of recommendation. This approach will permit the production of the first important practice guidelines on this topic.

[1]  D. Spyker,et al.  2011 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th Annual Report , 2012, Clinical toxicology.

[2]  Richard G. White,et al.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update , 2011, European Respiratory Journal.

[3]  R. Hoffman,et al.  Blood purification in toxicology: nephrology's ugly duckling. , 2011, Advances in chronic kidney disease.

[4]  R. Hoffman,et al.  Use of hemodialysis and hemoperfusion in poisoned patients. , 2008, Kidney international.

[5]  G. Guyatt,et al.  What is “quality of evidence” and why is it important to clinicians? , 2008, BMJ : British Medical Journal.

[6]  Alvin C Bronstein,et al.  2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS) , 2007, Clinical toxicology.

[7]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[8]  P I Dargan,et al.  An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose , 2002, Emergency medicine journal : EMJ.

[9]  B. Bailey,et al.  Comparison of patients hemodialyzed for lithium poisoning and those for whom dialysis was recommended by PCC but not done: what lesson can we learn? , 2000, Clinical nephrology.

[10]  D. Barceloux,et al.  American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning , 1999, Journal of toxicology. Clinical toxicology.

[11]  G. Schreiner The role of hemodialysis (artificial kidney) in acute poisoning. , 1958, A.M.A. archives of internal medicine.

[12]  L. Kyle,et al.  The application of hemodialysis to the treatment of barbiturate poisoning. , 1953, The Journal of clinical investigation.

[13]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[14]  Kathryn Fitch,et al.  The RAND/UCLA Appropriateness Method User's Manual , 2001 .

[15]  W. Watson,et al.  American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. , 1999, Journal of toxicology. Clinical toxicology.

[16]  D. Spiegelhalter,et al.  Consensus development methods, and their use in clinical guideline development. , 1998, Health technology assessment.